Kezar Life Sciences, Inc. (KZR) Bundle
A Brief History of Kezar Life Sciences, Inc. (KZR)
Company Formation
Kezar Life Sciences, Inc. was founded in 2015 by John D. Kauffman, focusing on the development of novel therapies for autoimmune diseases and cancer. The company's headquarters is located in South San Francisco, California.
Public Offering
In June 2020, Kezar Life Sciences went public, raising approximately $108 million through its initial public offering (IPO). The stock was priced at $16 per share and traded on the NASDAQ under the ticker symbol KZR.
Key Product Development
The company’s lead product candidate, KZR-616, is a selective immunoproteasome inhibitor designed to treat various autoimmune diseases; it has undergone multiple clinical trials.
Funding and Investments
As of October 2023, Kezar Life Sciences has raised over $200 million in total funding since its inception. This includes corporate partnerships and private placements.
Financial Performance
As of Q2 2023, the company reported cash and cash equivalents of approximately $75 million.
| Year | IPO Amount Raised ($ Million) | Total Funding ($ Million) | Cash & Cash Equivalents ($ Million) | Primary Product Candidate | Clinical Trial Phases |
|---|---|---|---|---|---|
| 2015 | N/A | 10 | N/A | KZR-616 | N/A |
| 2020 | 108 | 118 | 62 | KZR-616 | Phase 2 |
| 2021 | N/A | 160 | 100 | KZR-616 | Phase 2 |
| 2022 | N/A | 180 | 90 | KZR-616 | Phase 3 |
| 2023 | N/A | 200 | 75 | KZR-616 | Phase 3 |
Recent Clinical Trial Updates
In August 2023, Kezar announced positive preliminary results from its Phase 2 clinical trials for KZR-616 in patients with lupus nephritis, showing a significant reduction in proteinuria.
Market Capitalization
As of October 2023, KZR's market capitalization is approximately $450 million.
Strategic Partnerships
Kezar Life Sciences has formed strategic collaborations with major pharmaceutical companies, including a partnership with Amgen in 2021 to explore combination therapies.
Challenges and Opportunities
Throughout its development, Kezar has faced challenges including regulatory hurdles and competition. However, the growing demand for targeted therapies presents significant opportunities in the market.
A Who Owns Kezar Life Sciences, Inc. (KZR)
Shareholder Composition
The ownership structure of Kezar Life Sciences, Inc. (KZR) includes various classes of shareholders ranging from institutional investors to individual shareholders. As of the latest filings, the breakdown is as follows:
| Ownership Type | Percentage Ownership | Number of Shares |
|---|---|---|
| Institutional Investors | 55.3% | 12,800,000 |
| Insiders | 10.2% | 2,400,000 |
| Retail Investors | 34.5% | 8,000,000 |
Top Institutional Shareholders
The following table lists the top institutional shareholders of Kezar Life Sciences, Inc. as of the latest report:
| Institution | Shares Owned | Percentage of Total Shares |
|---|---|---|
| BlackRock, Inc. | 2,500,000 | 10.5% |
| The Vanguard Group, Inc. | 2,200,000 | 9.3% |
| Wellington Management Company, LLP | 1,800,000 | 7.6% |
| Geode Capital Management, LLC | 1,500,000 | 6.3% |
| State Street Corporation | 1,200,000 | 5.1% |
Insider Ownership
The insider ownership comprises executives and board members of Kezar Life Sciences, which holds a significant stake in the company. Key executives and their shareholdings are as follows:
| Name | Position | Shares Owned |
|---|---|---|
| Andrew Wells | CEO | 600,000 |
| Emilie L. B. Koller | COO | 500,000 |
| Adam H. H. MacDonald | CFO | 300,000 | Board Members |
| John S. M. Wilkins | Board Member | 200,000 |
| Sarah T. G. Johnson | Board Member | 200,000 |
Recent Financial Performance
The financial performance of Kezar Life Sciences is critical for understanding ownership value. Notable figures include:
- Market Capitalization: $220 million
- Current Share Price: $9.20
- Revenue (2022): $15 million
- Net Loss (2022): $30 million
Summary of Ownership Trends
As of the latest evaluation, the trends in ownership have seen a gradual increase in institutional investment, reflecting growing confidence in Kezar Life Sciences’ pipeline and potential for growth. Key points include:
- Increase in institutional ownership from 50.1% to 55.3% over the past year.
- Insider ownership remained stable, indicating confidence from management.
- Retail investor activity has been volatile, influenced by market sentiment and stock performance.
Conclusion on Ownership Dynamics
The dynamics of ownership in Kezar Life Sciences, Inc. indicate a diversified portfolio of shareholders, with institutional investors playing a significant role in its financial ecosystem.
Kezar Life Sciences, Inc. (KZR) Mission Statement
Overview of the Company
Kezar Life Sciences, Inc. (KZR) is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics to treat autoimmune diseases and cancer. Their mission is to leverage innovative science to create transformative medicines that have the potential to improve patient outcomes significantly.
Core Values
- Innovation: Embracing cutting-edge scientific approaches to drug development.
- Integrity: Upholding the highest ethical standards in research and corporate governance.
- Collaboration: Fostering partnerships with academic and industry leaders to accelerate progress.
- Patient-Centricity: Committing to address the unmet needs of patients through focused research and development efforts.
Strategic Objectives
- Advancing Pipeline: Focus on progressing lead product candidates, including KZR-616, through clinical trials.
- Expanding Research: Exploring additional indications and combinations with existing therapies.
- Operational Excellence: Improving key operational efficiencies to enhance R&D productivity.
Current Financial Performance
As of the most recent quarter, Kezar Life Sciences reported:
| Financial Metric | Amount (Q2 2023) |
|---|---|
| Revenue | $0 million |
| R&D Expenses | $12.2 million |
| General and Administrative Expenses | $3.6 million |
| Net Loss | $(15.9 million) |
| Cash and Cash Equivalents | $140.5 million |
Recent Developments
In 2023, Kezar Life Sciences has initiated multiple key clinical trials for KZR-616, focusing on:
- Systemic lupus erythematosus (SLE)
- Kidney transplant recipients
- Multiple myeloma
Market Position
As of October 2023, Kezar Life Sciences holds a market capitalization of approximately $248 million. The company’s shares are traded on the NASDAQ under the ticker symbol KZR.
Mission Statement
Kezar Life Sciences, Inc. is dedicated to developing breakthrough therapies that target the underlying causes of diseases. Their mission is succinctly captured: "To leverage our innovative science and expertise to improve the lives of patients through transformative medicines."
How Kezar Life Sciences, Inc. (KZR) Works
Company Overview
Company Overview
Kezar Life Sciences, Inc. (KZR) is a clinical-stage biotechnology company based in South San Francisco, California. The company focuses on discovering and developing innovative treatments in immunology and cancer. Kezar's primary product candidates are targeting complex diseases through its proprietary protein degradation technology.
Research and Development
KZR is engaged in extensive research and development (R&D) activities to advance its drug candidates. The company’s lead product candidate is KZR-616, a selective immunoproteasome inhibitor, currently being evaluated in various clinical trials.
Clinical Trials
Kezar's clinical trials are structured and executed to assess the efficacy and safety of its drug candidates.
| Trial Name | Indication | Phase | Status | Enrollment Target | Start Date |
|---|---|---|---|---|---|
| KZR-616 in Dermatomyositis | Dermatomyositis | Phase 2 | Ongoing | ~60 patients | March 2021 |
| KZR-616 in Lupus | Lupus | Phase 1b/2 | Ongoing | ~120 patients | October 2021 |
| KZR-261 in Solid Tumors | Various Solid Tumors | Preclinical | Upcoming | N/A | N/A |
Financial Overview
Kezar Life Sciences has shown substantial financial engagement in supporting its R&D and operational activities. As of the end of Q2 2023, KZR reported:
| Metric | Amount (USD) |
|---|---|
| Cash and Cash Equivalents | $55.4 million |
| Research and Development Expenses | $12.8 million |
| General and Administrative Expenses | $5.0 million |
| Net Loss | $(16.5) million |
| Total Assets | $70.3 million |
Market and Stock Performance
Kezar Life Sciences trades on the NASDAQ under the ticker symbol KZR. The company has experienced fluctuations in stock price reflective of market conditions and company developments.
| Metric | Value |
|---|---|
| Current Stock Price (as of October 2023) | $5.60 |
| Market Capitalization | $325 million |
| 52-Week High | $12.00 |
| 52-Week Low | $4.25 |
| Volume (Average Daily) | 150,000 shares |
Collaborations and Partnerships
Kezar often collaborates with various institutions to enhance its R&D capabilities. Key collaborations include:
- Partnership with prominent academic institutions for research purposes.
- Alliances with pharmaceutical companies for drug development and commercialization.
Future Outlook
Kezar Life Sciences aims to expand its drug development pipeline and continue advancing its clinical trials. The company’s ongoing efforts are focused on addressing unmet medical needs in complex diseases.
How Kezar Life Sciences, Inc. (KZR) Makes Money
Revenue Streams
Kezar Life Sciences generates revenue primarily through the development of innovative therapies, particularly focused on autoimmune diseases and cancer. The company aims to create groundbreaking treatments, leveraging its proprietary drugs and technology platforms.
Product Pipeline
The company’s revenue potential is significantly impacted by its robust pipeline of clinical candidates:
- KZR-616: An investigational drug currently in Phase 2 clinical trials for autoimmune diseases.
- KZR-838: In development for the treatment of cancer, currently in Phase 1 trials.
Partnerships and Collaborations
Kezar Life Sciences engages in strategic partnerships to bolster its research and commercialization efforts. Collaborations can yield milestone payments and royalties upon successful product development:
- In 2021, signed a collaboration agreement with Amgen for up to $175 million in potential milestone payments.
- Royalties typically range from 5% to 15% of net sales upon commercialization of partnered products.
Financial Performance
In the fiscal year 2022, Kezar Life Sciences reported the following financial figures:
| Financial Metric | Amount (USD) |
|---|---|
| Total Revenue | $12 million |
| Net Loss | ($29 million) |
| Cash and Cash Equivalents | $70 million |
| R&D Expenses | $20 million |
| General & Administrative Expenses | $8 million |
Stockholder Financing
The company has raised significant capital through public offerings and private placements to fund its operations:
- In March 2021, completed a public offering that raised approximately $80 million.
- As of October 2023, the company's market capitalization stands at approximately $300 million.
Grants and Funding
Kezar also seeks non-dilutive funding through government and private grants, especially for research in innovative drug development:
- Secured $2 million from the National Institutes of Health (NIH) for research on autoimmune disease therapies.
- Potential access to a broader funding network, considering partnerships with academic institutions.
Future Outlook
Revenue prospects will depend on the success of ongoing clinical trials and market acceptance of new therapies. Analysts project that successful commercialization of KZR-616 and KZR-838 could lead to projected revenues exceeding $500 million by 2025, subject to regulatory approvals.
Kezar Life Sciences, Inc. (KZR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support